Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 574

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Dr Marina Garassino speaks to ecancer at ESMO 2019 in Barcelona commenting on the FLAURA trial.

The trial was looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.

Dr Garassino comments because smaller facilities may not have the capability to do full sequencing, having multiple treatment options is still important in order to personalise treatment for these patients where possible.

Watch the press conference here

Watch Dr Pilar Garrido's comment here

Read more about the study here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation